The pharmaceutical company Merck "paid an undisclosed sum to Elsevier to produce several volumes of a publication that had the look of a peer-reviewed medical journal, but contained only reprinted or summarized articles -- most of which presented data favorable to Merck products." The Australasian Journal of Bone and Joint Medicine carried "ads for Fosamax, a Merck drug for osteoporosis, and Vioxx" and "appeared to act solely as marketin
"Biotechnology companies are keeping university scientists from fully researching the effectiveness and environmental impact of the industry’s genetically modified crops, according to an unusual complaint issued by a group of those scientists," reports Andrew Pollack.
In 2002, an independent study on hormone replacement therapy was halted, because the drugs were strongly linked to an "increased risk for breast cancer, heart disease, stroke and blood clots" in women. The same year, the University of Wisconsin-Madison began offering an online course, "funded entirely by a $12 million grant from Wyeth Pharmaceuticals," that "promoted hormone therapy, touted its benefits and downplayed its risks." Wyeth makes two hormone therapy drugs, Prempro and Premarin.
According to internal documents, the pharmaceutical company Wyeth "paid ghostwriters to produce medical journal articles favorable to its female hormone replacement therapy Prempro." As early as 1997, Wyeth paid the "medical writing firm" DesignWrite to publish favorable journal articles about Prempro under academics' names.
The Canadian Association of University Teachers has strongly condemned a new lawsuit by the Apotex pharmaceutical company against Dr. Nancy Olivieri. As a liver specialist at the University of Toronto, Olivieri first came under attack from Apotex in 1996 when she notified her patients that she had detected toxic side effects while conducting an Apotex-sponsored study of the company's drug, deferiphone.